TCGA-69-8255-01A-11R-2287-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.660
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.470
- OXIDATIVE_PHOSPHORYLATION+0.420
- XENOBIOTIC_METABOLISM+0.390
- BILE_ACID_METABOLISM+0.360
- MTORC1_SIGNALING+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.350
- SPERMATOGENESIS+0.350
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- TGF_BETA_SIGNALING-0.480
- UV_RESPONSE_DN-0.450
- NOTCH_SIGNALING-0.440
- ANGIOGENESIS-0.410
- HEDGEHOG_SIGNALING-0.400
- WNT_BETA_CATENIN_SIGNALING-0.390
- APICAL_JUNCTION-0.370
- P53_PATHWAY-0.370
- ESTROGEN_RESPONSE_EARLY-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.891 |
| 2 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.829 |
| 3 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.825 |
| 4 | TCGA-C8-A1HG-01A-11R-A137-07 | — | B | 0.819 |
| 5 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.816 |
| 6 | SRR1313151 | — | E | 0.812 |
| 7 | SRR8518141 | — | E | 0.811 |
| 8 | SRR8518323 | — | E | 0.810 |
| 9 | MBCProject_5971_T2_RNA | — | C | 0.809 |
| 10 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.660 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.390 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |